ANTI-PD1 IN COMBINATION WITH AN INHIBITOR OF PCSK9 TO INCREASE MHC CLASS I MOLECULE EXPRESSION ON TUMOR CELLS AS IMMUNOTHERAPY FOR NSCLC
$1,261,852FY2021Defense Health AgencyDOD
Duke University, Durham NC
Investigators
View source on USAspending →ANTI-PD1 IN COMBINATION WITH AN INHIBITOR OF PCSK9 TO INCREASE MHC CLASS I MOLECULE EXPRESSION ON TUMOR CELLS AS IMMUNOTHERAPY FOR NSCLC · GrantIndex